Repurposing the mucolytic cough suppressant and TMPRSS2 protease inhibitor bromhexine for the prevention and management of SARS-CoV-2 infection

Pharmacol Res. 2020 Jul;157:104837. doi: 10.1016/j.phrs.2020.104837. Epub 2020 Apr 22.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antitussive Agents*
  • Betacoronavirus
  • Bromhexine*
  • COVID-19
  • Coronavirus Infections
  • Expectorants
  • Humans
  • Pandemics
  • Peptidyl-Dipeptidase A
  • Pneumonia, Viral
  • Protease Inhibitors
  • SARS Virus*
  • SARS-CoV-2
  • Virus Internalization

Substances

  • Antitussive Agents
  • Expectorants
  • Protease Inhibitors
  • Peptidyl-Dipeptidase A
  • Bromhexine